ABBV · News · 20261102N

Immunology and Neuroscience Demand

AbbVie Inc. · 2026-11-02 · Importance 36 · Surprise 40

AbbVie reported broad commercial momentum across its immunology and neuroscience portfolios in the third quarter. SKYRIZI, RINVOQ, and VRAYLAR each delivered double-digit revenue increases, and management said nine key products grew at double-digit rates. The reports specifically cite continued demand for SKYRIZI and RINVOQ and progress in new neuroscience indications.

Key facts

• AbbVie’s SKYRIZI, RINVOQ, and VRAYLAR each delivered double-digit revenue increases in the third quarter. source
• AbbVie’s newer growth engines generate more than twelve times Humira’s quarterly revenue. source